Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2008

Raven Inks Manufacturing Deal with CMC to Help Advance RAV 18 into the Clinic

  • Raven biotechnologies entered into an agreement under which CMC Icos Biologics will create a production cell line for Raven’s next IND candidate, RAV18. Raven is targeting  to file in 2009.

    The product is a humanized antibody targeting the ADAM9 protein on cells. ADAM9 is expressed on solid tumors and is thought to contribute to disease progression and metastasis.

    A number of carcinoma cell lines have been shown to amplify the gene for ADAM9 and to overexpress the protein. This overexpression has been reported in pancreatic, prostate, gastric, breast, and lung cancers.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »